Estelle-35 ED (84 tablets)

The chemical name of cyproterone acetate is 6-chloro—3,20-dioxo-1ß,2ß-dihydro-3`H-cyclopropa[1,2]pregna-1,4,6-trien-17-yl acetate. Estelle-35 ED is used to treat women who suffer from conditions arising from increased secretion of or increased response to androgen (male) hormones. Such conditions include acne, or moderately increased growth of facial and body hair (hirsutism). Estelle 35-ED should be withdrawn 3 to 4 cycles after the treated condition has been completely resolved. Estelle-35 ED provides effective oral contraception in women being treated for androgen-ependent diseases. Pack quantities: Three calendar packs of 28 tablets; sample pack containing one calendar pack of 28 tablets. Indications: ESTELLE-35 ED is indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. ESTELLE-35 and ESTELLE-35 ED are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. ESTELLE-35 and ESTELLE-35 ED are also indicated for treating the symptoms of polycystic ovary syndrome. Presentation: One calendar pack contains 21 yellow active tablets and 7 white inactive tablets. Each active tablet is a yellowish buff, round, biconvex tablet, plain on both sides with a diameter of 5.0mm, containing 2 mg cyproterone acetate and 35 micrograms (0.035 mg) ethinyloestradiol. Each inactive tablet is a white, round, biconvex, tablet, plain on both sides with a diameter of 7.1 mm. Storage: Shelf life is 3 years. Store below 30 °C. Packaging: Estelle-35 ED is a calendar pack containing 21 small yellow active tablets and 7 larger white non- active tablets per blister strip. Available as packs of 84 tablets.